Orca Bio
Orca Bio is a biotechnology company specializing in the development of advanced cell therapies aimed at improving patient outcomes and reducing treatment risks, with a focus on combating cancerous blood and immune system diseases.
Company Overview
Orca Bio is a biotechnology company specializing in next-generation cell therapies aimed at providing significantly better outcomes with dramatically fewer risks. The company focuses on transforming cell therapy, one cell at a time, leveraging its proprietary mix of natural immune cells and stem cells to create a designer immune system. Orca Bio operates with a vision to expand the life-changing benefits of cell therapies to more patients.
History
Founded in 2016, Orca Bio originated from research conducted in the laboratory of Dr. Irv Weissman, a renowned stem cell pioneer at Stanford University. Since its inception, the company has dedicated itself to advancing the field of cell therapy, specifically targeting improvements in patient outcomes and reductions in treatment risks.
Cell Therapy Innovations
Orca Bio develops investigational cell therapies designed to replace a patient's cancerous blood and immune system with a healthy one. These therapies aim to improve survival rates and quality of life by delivering purified, high-precision treatments that address complications of traditional methods, such as Graft-versus-host disease (GvHD). The company’s proprietary technology involves a custom blend of immune cells and stem cells to create a designer immune system.
Recent Developments
At the 65th ASH Annual Meeting, Orca Bio presented positive data on its investigational therapies Orca-T and Orca-Q. These therapies are part of the company's portfolio aimed at providing enhanced effectiveness with fewer side effects. The presentation at this significant event underlines Orca Bio’s commitment to advancing cell therapy.
Manufacturing Capabilities
Orca Bio has developed its own manufacturing facilities and technologies, enabling the company to reliably deliver high-precision investigational cell therapies at scale. This infrastructure supports the company's mission to provide superior cell therapies with consistent quality and precision, thus offering better outcomes with fewer risks for patients.